Shu-hsia Chen, PhD
Emily Herrmann Chair in Immunology Research, Dr. Mary and Ron Neal Cancer Center
Director, Center for Immunotherapy Research
Professor of Oncology, Academic Institute
Full Member, Research Institute
Houston Methodist
Weill Cornell Medical College
Modulating Microglia in Alzheimer's Disease

Dr. Chen has focused her career on gene therapy and immune therapy to develop and identify the novel therapeutic modalities that can reconstruct or modulate the immune response. During the last decade at Icahn school of Medicine at Mount Sinai, she studied the mechanisms underlying the establishment of immune suppressive tumor microenvironment, which remains the major hurdle to the success of immune-based cancer therapies.

She is one of the pioneers in identification of the myeloid derived suppressor cell (MDSC) subset populations and their roles in the immune suppression in the tumor microenvironment. She is also the inventor for modulating myeloid suppressor cell function for treating autoimmune diseases and cancer. Currently she has an investigator-initiated Phase IIb clinical trial at Methodist Hospital that are derived from the research results generated in her laboratory.

Currently, she is an endowed Emily Herrmann Chair in Immunology Research, Director of Center for Immunotherapy Research at Neal Cancer Center of Excellence and Professor, Institute of Academic Medicine, and Methodist Research Institute (HMRI), Houston, Texas and Professor at Dep. Physiology, Biophysics and Systems Biology (PBSB), Weill Cornell School of Medicine, NY.